| Code | CSB-RA011664MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Siltuximab, targeting interleukin-6 (IL-6), a pleiotropic cytokine that plays a central role in immune response, inflammation, and hematopoiesis. IL-6 signals through membrane-bound and soluble IL-6 receptors, activating the JAK-STAT3 pathway to regulate acute phase responses, B-cell maturation, and T-cell differentiation. Dysregulated IL-6 signaling is implicated in numerous pathological conditions including Castleman's disease, rheumatoid arthritis, cytokine release syndrome, and various malignancies where it promotes tumor growth, angiogenesis, and resistance to therapy.
Siltuximab is a chimeric IgG1κ monoclonal antibody that binds human IL-6 with high affinity, neutralizing its biological activity by preventing interaction with both soluble and membrane-bound IL-6 receptors. This biosimilar provides researchers with a valuable tool for investigating IL-6-mediated signaling pathways, studying inflammatory disease mechanisms, and exploring therapeutic interventions in cytokine-driven disorders. It enables detailed examination of IL-6 biology in cellular and molecular research contexts.
There are currently no reviews for this product.